SK Bioscience Co

SK Bioscience Co Receivables

The Accounts Receivable of SK Bioscience Co (302440.KS) as of Nov 1, 2026 is 105.89 B KRW. In the previous year, Accounts Receivable was 18.23 B KRW — a change of 480.73% (higher).

Receivables

105.89 BKRW

YoY

480.73%

Last updated:

Accounts Receivable of SK Bioscience Co is 2024 105.89 B KRW. Accounts Receivable of SK Bioscience Co was 2023 18.23 B KRW. It decreases by 480.73% higher compared to the previous year.

The SK Bioscience Co Receivables history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Receivables
Date
Receivables
Jan 1, 2018
42.87 B KRW
Jan 1, 2019
32.24 B KRW
Jan 1, 2020
31.48 B KRW
Jan 1, 2021
39.03 B KRW
Jan 1, 2022
41.06 B KRW
Jan 1, 2023
18.23 B KRW
Jan 1, 2024
105.89 B KRW
The SK Bioscience Co Receivables history
YEARReceivablesYoY
105.89 BKRW+480.73%
18.23 BKRW-55.59%
41.06 BKRW+5.21%
39.03 BKRW+23.99%
31.48 BKRW-2.37%
32.24 BKRW-24.80%
42.87 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

SK Bioscience Co Stock analysis

What does SK Bioscience Co do? SK Bioscience Co Ltd is a South Korean biotechnology company headquartered in Seongnam, Gyeonggi-Do. The company went public on March 18, 2021, with its stock listed on the Korean Stock Exchange under the ticker 302440.KS. It operates within the health care sector, specifically in the biotechnology industry. SK Bioscience employs 1,067 people and focuses on the development and distribution of bio and vaccine products. The company distributes its products both domestically and internationally. While specific product names are mentioned in unverified sources, the company is known to be involved in the production of vaccines and infusion solutions. It also engages in technology export business, though detailed information about its technology or export markets is not provided. The company's website is https://www.skbioscience.co.kr/, where further information about its operations and products may be available. SK Bioscience does not disclose specific details about its product lines beyond the general categories of vaccines and infusion solutions, and it does not provide information on acquisitions, founding year, or key personnel. The company's activities are centered around biotechnology and healthcare, with a focus on vaccine development and distribution. Its market presence spans both domestic and international markets, though specific regions or countries are not specified. The company's financial data, including revenue and market capitalization, is not included in the provided information. SK Bioscience is a publicly traded company with a focus on biotechnology and healthcare innovation. SK Bioscience Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about SK Bioscience Co stock

Accounts Receivable of SK Bioscience Co is 105.89 B KRW in 2024.

Accounts Receivable of SK Bioscience Co changed from 18.23 B KRW to 105.89 B KRW, representing a 480.73% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Accounts Receivable SK Bioscience Co since 2006 – with annual values, charts, and detailed analysis.

Receivables represent money owed to the company by customers for goods or services delivered. High receivables relative to revenue may indicate collection issues.

Accounts Receivable's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Accounts Receivable's SK Bioscience Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — SK Bioscience Co

All Key Metrics — SK Bioscience Co